Event scheduled for Tuesday, December 2nd at 8:00 AM ETFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma,...
Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and...
German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an...
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm...
AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value...
- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset...
ORLANDO, Fla., Nov. 22, 2025 /PRNewswire/ -- This November at the ACAAI Annual Meeting 2025, one theme dominated the conversations: AI...
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launchCRANFORD,...
JERUSALEM, Nov. 20, 2025 /PRNewswire/ -- ViVac Pharma Ltd., a pioneering synthetic biology company advancing RNA–Lipid Nanoparticle (LNP) immunotherapies, announces the...
AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S....
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering...
Independent valuation reflects major advancement of OT-101 and Deciparticle™ nanomedicine platformSAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN...
Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiaryPartnership expected to...
Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy PipelineBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE)...
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free...
OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a...
SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical...
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is...
LED operating light market is experiencing robust expansion driven by rising procedural volumes, growing adoption of minimally invasive surgery, and...
DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics...